Vagina-View helps guide multichannel applicator placement during vaginal brachytherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm feasibility study investigates the Vagina-View device as a tool to visualize vaginal mucosal tumor involvement during MRI-guided intravaginal brachytherapy. The goal is to determine if VV can accurately guide MCA placement and reduce reliance on MRI, potentially lowering radiation exposure to healthy tissue and limiting treatment-related side effects. Importantly, VV imaging is used only for visualization and is not part of treatment planning or delivery. Primary endpoints focus on feasibility and positional accuracy of VV-assisted MCA placement.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any patient with gynecological cancer who is planned to receive MRI-guided intravaginal brachytherapy with an MCA applicator.
* Able to receive and understand verbal and written information regarding study and able to give written informed consent

Exclusion Criteria:

* Patient receiving brachytherapy with a different brachytherapy device.
* Patient with contraindications to MRI.

Where it's running

• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Using SCG142 TCR-T cells to treat HPV-related cancers

  This study is testing a new type of immune cell treatment called SCG142 TCR-T cells to see if it can help people with advanced cancers related to HPV.

  Recruiting Phase 1 The Affiliated Hospital of Qingdao University · Qingdao, Shandong · NCT06544720

• 3D printed applicators for treating gynecologic cancers

  This study is testing whether 3D-printed custom applicators can make radiation treatment more effective for patients with gynecologic cancers.

  Recruiting Royal North Shore Hospital · St Leonards, New South Wales · NCT06432478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.